SCYX

SCYNEXIS is no longer an operating drug company — it is a royalty-plus-pipeline vehicle. Its approved asset (BREXAFEMME/ibrexafungerp) was licensed to GSK in May 2023, so reported revenue is milestone/royalty income and is inherently lumpy: $140M in FY2023 (the GSK upfront, driving the only profitable year at +$67M net income), collapsing to $3.75M in FY2024, then rebounding to $20.6M in FY2025 (+449.9%). At a $198M market cap that revenue base is real but not a durable growth curve you can extrapolate — the 9.6x P/S is close to meaningless applied to milestone-driven receipts. What matters more is that the loss profile is genuinely improving: net loss narrowed to -$8.61M (from -$21.3M), operating loss to -$16.1M, and operating cash burn to just -$5.28M as R&D was cut 15.6% to $22.3M. The balance sheet is clean — $49.4M equity against only $9.65M liabilities (0.20x) — so there is no solvency stress today.

The pipeline is where the story lives, and the 10-K gives a credible update. SCY-247, a second-generation fungerp, completed the SAD/MAD portions of a Phase 1 in 88 subjects: no serious or severe TEAEs, dose-proportional PK, and the 200mg/300mg once-daily cohorts hit or exceeded target efficacious exposure against resistant strains (C. auris, echinocandin-resistant C. glabrata) that defeat current therapies. It carries QIDP and Fast Track, implying 10 years of exclusivity if approved. An IV formulation entered Phase 1 in Q1 2026 and a Phase 2 proof-of-concept in invasive candidiasis is planned for 2026. That is a real, differentiated program in a genuine unmet-need niche.